Track topics on Twitter Track topics that are important to you
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
MONDAY, Oct. 3, 2016 -- The blood thinner Xarelto may pose a slightly greater risk of serious bleeding than Pradaxa in patients with the abnormal heartbeat known as atrial fibrillation, new research s...
Biospectrum Pradaxa, Xarelto, and Eliquis, which are all currently available, will see improved uptake over the forecas...
Portola has said European regulators are to review its anticoagulant antidote, IndexXa (andexanet alfa), just days after the US regulator rejected the drug. California-based Portola said the Europea...
* Believes statements published in 'Handelsblatt' on Nov. 9. about Xarelto are misleading
NewsPhase 3b study shows significantly less bleeding with Xarelto (rivaroxaban) compared to Warfarin in people with non-valvular atrial fibrillation following percutaneous coronary intervention with s...
The U.S. Food and Drug Administration on Tuesday said it has determined the widely-used blood thinner Xarelto to be safe and effective for patients with the heart condition atrial fibrillation after s...
Oct 11 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it has determined the widely-used blood thinner Xarelto to be safe and effective for patients with the heart condition atrial f...
NewsPharmaceutical company Boehringer Ingelheim Pharmaceuticals Inc., presented two studies at the American Society of Hematology Annual Meeting in San Diego, which showed patients who were newly diag...
Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due to their ease of use and the lack of monitoring requirements. With gro...